Location: Animal Disease Research
Project Number: 2090-32000-040-013-R
Project Type: Reimbursable Cooperative Agreement
Start Date: Oct 1, 2019
End Date: Jun 30, 2022
1: Identify B. bovis blood and tick stage antigens that are conserved and expressed on the surface of parasites in field isolates from U.S., Israel and Mexico. 2. Determine the functional and immunological properties of the identified antigens in field isolates from U.S., Israel and Mexico. 3. Evaluate the efficacy of a multivalent vaccine containing the identified antigens to protect cattle against B. bovis disease and transmission.
Previous vaccine development efforts against Babesia parasites of livestock have largely focused on live attenuated parasite blood stages. Recently, vaccine development efforts have shifted to explore the potential of specific blood-stage parasite immunodominant proteins. Unfortunately, immunization with these recombinant proteins failed to induce protective immunity equivalent to that of the live attenuated vaccines. This disappointing failure to induce protection suggests that critical antigens have yet to be identified, and the limited antigen repertoire available is insufficient to induce protection against bovine babesiosis. In addition, genetic diversity of B. bovis strains has been discovered demonstrating conserved proteins between isolates are critical for the development of efficient vaccines to B. bovis. In this proposal we will identify conserved proteins amongst B. bovis isolates from U.S., Israel and Mexico. The strategy presented in this proposal will allow us to determine conserved antigens for B. bovis vaccines development.